HPTN 083 Launches

Injectable Cabotegravir
Dec 20, 2016

The HPTN has launched HPTN 083, the first study to test efficacy and safety of injectable cabotegravir (CAB) for PrEP. The study will evaluate whether injectable CAB can safely protect men who have sex with men (MSM) and transgender women (TGW) who have sex with men from acquiring HIV as well as daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC). If found to be safe and effective for HIV pre-exposure prophylaxis, also known as PrEP, injectable CAB may be easier for some people to adhere to than daily oral TDF/FTC. The U.S., Canada, South Africa, Kenya, Peru, France and Australia are among countries where TDF/FTC is approved for use as PrEP.

Read the FAQ